Impact of prior treatment history on efficacy of Risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials

被引：0

作者：

Strober, B. ^{[1
,2
]}

Lambert, J. ^{[3
]}

Gu, Y. ^{[4
]}

Zhan, T. ^{[4
]}

Thompson, E. Z. ^{[5
]}

Valdecantos, W. C. ^{[4
]}

Menter, A. ^{[6
]}

机构：

[1] Univ Connecticut, Ctr Hlth, Farmington, CT USA

[2] Prob Med Res, Farmington, CT USA

[3] Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium

[4] AbbVie Inc, N Chicago, IL USA

[5] AbbVie Inc, Redwood City, CA USA

[6] Baylor Univ, Med Ctr, Div Dermatol, Dallas, TX USA

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P100

引用

页码：117 / 117

页数：1

共 50 条

[1] Impact of Prior Treatment History on Efficacy of Risankizumab Compared with Placebo in Patients with Moderate-to-Severe Plaque Psoriasis: Integrated Analyses from Three Phase 3 Trials
Strober, B.
Lambert, J.
Gu, Y.
Thompson, E. H.
Valdecantos, W. C.
Menter, A.
EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E24
[2] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
Lebwohl, M.
Ghislain, P.
Kerdel, F.
Gu, Y.
Valdes, J. M.
Thompson, E. H.
Lynde, C.
EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E25 - E25
[3] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
Lebwohl, M.
Ghislain, P-D
Kerdel, F.
Gu, Y.
Valdes, J.
Thompson, E. H.
Lynde, C.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 115 - 116
[4] Durable efficacy of risankizumab compared with ustekinumab across subgroups of patients with moderate-to-severe plaque psoriasis: Integrated analysis of two phase 3 trials
Foley, Peter
Strober, Bruce
Valdecantos, Wendell C.
Photowala, Huzefa
Zhan, Tianyu
Menter, Alan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB49 - AB49
[5] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
Ryan, C.
Crowley, J.
Valdecantos, W.
Wu, T.
Reich, K.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 21
[6] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
Ryan, Caitriona
Crowley, Jeffrey
Valdecantos, Wendell
Wu, Tianshuang
Reich, Kristian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
[7] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
Reich, K.
Gooderham, M.
Thaci, D.
Crowley, J. J.
Ryan, C.
Kruger, J. G.
Tsai, T.
Flack, M.
Gu, Y.
Williams, D. A.
Thompson, E. H.
Paul, C.
EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
[8] Efficacy of risankizumab in moderate-to-severe plaque psoriasis by baseline characteristics and prior therapies
Strober, B.
Valdecantos, W.
Zhan, T.
Lambert, J.
Menter, A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 42 - 43
[9] Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 IMMvent Trial
Reich, Kristian
Gooderham, Melinda
Thaci, Diamant
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB52 - AB52
[10] Efficacy and safety of risankizumab (RZB) compared with adalimumab (ADA) in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial
Reich, K.
Gooderham, M.
Thaci, D.
Crowley, J. J.
Ryan, C.
Krueger, J. G.
Tsai, T. -F.
Flack, M.
Gu, Y.
Williams, D. A.
Thompson, E. H. Z.
Paul, C.
EXPERIMENTAL DERMATOLOGY, 2018, 27 : 9 - 10

← 1 2 3 4 5 →